Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

NCT00212693
completedphase_2

A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)

NCT00694941
completedphase_2

Effects of ONO-2506PO in Patients With Alzheimer's Disease

NCT00083421
completedphase_2

Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00403104

Clinical Trials (4)

Showing 4 of 4 trials
NCT00212693Phase 2

Controlled Study of ONO-2506PO in Patients With Parkinson's Disease in Japan

Completed
NCT00694941Phase 2

A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT00083421Phase 2

Effects of ONO-2506PO in Patients With Alzheimer's Disease

Completed
NCT00403104Phase 2

Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4